Paul Newbold

8.9k total citations · 3 hit papers
88 papers, 4.4k citations indexed

About

Paul Newbold is a scholar working on Physiology, Pulmonary and Respiratory Medicine and Emergency Medical Services. According to data from OpenAlex, Paul Newbold has authored 88 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Physiology, 36 papers in Pulmonary and Respiratory Medicine and 10 papers in Emergency Medical Services. Recurrent topics in Paul Newbold's work include Asthma and respiratory diseases (46 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (26 papers) and Respiratory and Cough-Related Research (15 papers). Paul Newbold is often cited by papers focused on Asthma and respiratory diseases (46 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (26 papers) and Respiratory and Cough-Related Research (15 papers). Paul Newbold collaborates with scholars based in United States, United Kingdom and Canada. Paul Newbold's co-authors include R. P. Hope, Clive W. J. Granger, Stephen J. Taylor, John M. Gottman, Gene V. Glass, Victor L. Willson, Mitchell Goldman, Ian Hirsch, James Zangrilli and Tuyet‐Hang Pham and has published in prestigious journals such as Journal of the American Statistical Association, Gastroenterology and PLoS ONE.

In The Last Decade

Paul Newbold

85 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Forecasting Economic Time Series

1979 698 citations Paul Newbold et al. profile →
Statistics for Business and Economics.

1988 507 citations Paul Newbold et al. profile →
Design and Analysis of Time-Series Experiments.

1976 421 citations Paul Newbold et al. profile →

Peers

Countries citing papers authored by Paul Newbold

Since Specialization

Citations

This map shows the geographic impact of Paul Newbold's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Newbold with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Newbold more than expected).

Fields of papers citing papers by Paul Newbold

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Newbold. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Newbold. The network helps show where Paul Newbold may publish in the future.

Co-authorship network of co-authors of Paul Newbold

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Newbold. A scholar is included among the top collaborators of Paul Newbold based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Newbold. Paul Newbold is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Multivariate Cluster Analyses to Characterize Asthma Heterogeneity and Benralizumab Responsiveness 2024 ·The Journal of Allergy and Clinical Immunology In Practice ·Xingnan Li, Paul Newbold, Rohit Katial, Ian Hirsch, Huashi Li, Ubaldo J. Martin, Deborah A. Meyers, Eugene R. Bleecker	4
2	Clinical Implications of Longitudinal Blood Eosinophil Counts in Patients With Severe Asthma 2023 ·The Journal of Allergy and Clinical Immunology In Practice ·Eugene R. Bleecker, Deborah A. Meyers, Dean Billheimer, Huashi Li, Paul Newbold, (unknown), Ian Hirsch, Rohit Katial, Xingnan Li	11
3	Eosinophil-derived neurotoxin: A biologically and analytically attractive asthma biomarker 2021 ·PLoS ONE ·Bart P. F. Rutten, Simon Young, Magdalena Rhedin, Marita Olsson, Nisha Kurian, (unknown), Augusta Beech, Mark Fidock, Paul Newbold, Dave Singh, Adam Platt, (unknown)	27
4	Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity 2021 ·European Respiratory Journal ·Rania Dagher, Varsha Kumar, Alan M. Copenhaver, Sandra Gallagher, (unknown), (unknown), Paul Newbold, Alison A. Humbles, Roland Kolbeck	35
5	Blood Eosinophil Count and Fractional Exhaled Nitric Oxide as a Combined Predictor of Treatment Response to Benralizumab for Patients with Severe, Eosinophilic Asthma 2021 ·Pneumologie ·Rohit Katial, James L. Kreindler, Ian Hirsch, Paul Newbold, (unknown)	1
6	The commutability of enzyme linked immunosorbent assays for the quantification of serum eosinophil-derived neurotoxin (EDN) 2021 ·Journal of Immunological Methods ·Bart P. F. Rutten, Simon Young, (unknown), (unknown), Mark Fidock, Paul Newbold, Dave Singh, Adam Platt, (unknown)	2
7	The relationship between airway immunoglobulin activity and eosinophils in COPD 2020 ·Journal of Cellular and Molecular Medicine ·Thomas Southworth, Andrew Higham, Umme Kolsum, Li J, Thomas R. Scott, Josiah Dungwa, Sriram Sridhar, Tuyet‐Hang Pham, Paul Newbold, Dave Singh	13
8	<p>Sputum <em>Streptococcus pneumoniae</em> is reduced in COPD following treatment with benralizumab</p> 2019 ·International Journal of COPD ·Leena George, Adam Wright, Vijay Mistry, Amanda Sutcliffe, Latifa Chachi, Koirobi Haldar, Mohammadali Yavari Ramsheh, Matthew Richardson, René van der Merwe, Ubaldo J. Martin, Paul Newbold, Christopher E. Brightling	9
9	Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases 2019 ·Respiratory Research ·Sriram Sridhar, Hao Liu, Tuyet‐Hang Pham, Gautam Damera, Paul Newbold	49
10	Biological exacerbation clusters demonstrate asthma and chronic obstructive pulmonary disease overlap with distinct mediator and microbiome profiles 2018 ·Journal of Allergy and Clinical Immunology ·Michael A. Ghebre, (unknown), Sarah Diver, Dhananjay Desai, Mona Bafadhel, Koirobi Haldar, Tatiana Kebadze, E. Suzanne Cohen, Paul Newbold, Laura Rapley, Joanne Woods, Paul Rugman, Ian Pavord, Sebastian L. Johnston, Michael R. Barer, Richard May, Christopher E. Brightling	114
11	Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn’s Disease: A Phase 2a Study 2017 ·Gastroenterology ·Bruce E. Sands, Jingjing Chen, Brian G. Feagan, Mark Penney, William A. Rees, Silvio Danese, Peter Higgins, Paul Newbold, Raffaella Faggioni, Kaushik Patra, Jing Li, Paul Klekotka, Chris Morehouse, Erik Pulkstenis, Jörn Drappa, René van der Merwe, Robert A. Gasser	223
12	Reductions in eosinophil biomarkers by benralizumab in patients with asthma 2016 ·Respiratory Medicine ·Tuyet‐Hang Pham, Gautam Damera, Paul Newbold, Koustubh Ranade	139
13	A Sputum Proteomic Signature That Associates with Increased IL-1β Levels and Bacterial Exacerbations of COPD 2016 ·Lung ·Gautam Damera, Tuyet‐Hang Pham, Jianchun Zhang, Christine K. Ward, Paul Newbold, Koustubh Ranade, Sanjay Sethi	23
14	Biological clustering supports both “Dutch” and “British” hypotheses of asthma and chronic obstructive pulmonary disease 2014 ·Journal of Allergy and Clinical Immunology ·Michael A. Ghebre, Mona Bafadhel, Dhananjay Desai, E. Suzanne Cohen, Paul Newbold, Laura Rapley, (unknown), Paul Rugman, Ian Pavord, Chris Newby, Paul R. Burton, Richard May, Christopher E. Brightling	95
15	Detection of COPD Exacerbations and Compliance With Patient-Reported Daily Symptom Diaries Using a Smartphone-Based Information System 2013 ·CHEST Journal ·Neil Johnston, Kim Lambert, (unknown), Maria Gerhardsson de Verdier, Tim Higenbottam, (unknown), Paul Newbold, Martin Jenkins, Geoffrey R. Norman, Peter Coyle, Andrew McIvor	26
16	A randomised controlled trial of the effect of automated interactive calling combined with a health risk forecast on frequency and severity of exacerbations of COPD assessed clinically and using EXACT PRO 2011 ·Primary Care Respiratory Journal ·David Halpin, (unknown), (unknown), Mark L Levy, Peter Coyle, (unknown), Paul Newbold, (unknown)	44
17	Measuring whole‐body neutrophil redistribution using a dedicated whole‐body counter and ultra‐low doses of ¹¹¹Indium 2010 ·European Journal of Clinical Investigation ·Katy Szczepura, (unknown), Chandra K. Solanki, Kottekkattu Balan, Paul Newbold, Charlotte Summers, Edwin R. Chilvers, A. Michael Peters	11
18	Sputum IL-5 Concentration Is Associated with a Sputum Eosinophilia and Attenuated by Corticosteroid Therapy in COPD 2009 ·Respiration ·Mona Bafadhel, (unknown), Roshan Siva, Michael McCormick, William Monteiro, Paul Rugman, P M Dodson, Ian Pavord, Paul Newbold, Christopher E. Brightling	42
19	The clinical utility of biomarkers in asthma and COPD 2008 ·Current Opinion in Pharmacology ·Noel Snell, Paul Newbold	32
20	Statistics for business & economics 1995 ·Paul Newbold	101

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact